Muralidhar Vinayak, Nipp Ryan D, Ryan David P, Hong Theodore S, Nguyen Paul L, Wo Jennifer Y
1 Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts 2 Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts 3 Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 4 Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Dis Colon Rectum. 2016 Mar;59(3):187-93. doi: 10.1097/DCR.0000000000000532.
Larger tumor size and lymph node involvement are traditionally associated with increased colon cancer-specific mortality.
We sought to determine whether patients with very small tumors associated with lymph node involvement are at paradoxically increased risk of colon cancer-specific mortality in comparison with those who have larger tumors and lymph node involvement.
This is a retrospective cohort study using the Surveillance, Epidemiology, and End Results database.
Geographic areas included in one of the 18 Surveillance, Epidemiology, and End Results registries were used.
We identified 99,594 patients with nonmetastatic colon adenocarcinoma treated with surgery between 1988 and 2001.
The primary predictor variables were regional lymph node involvement and primary tumor size by longest dimension, grouped into the following predetermined strata: <5 mm, 5 to 19 mm, 20 to 39 mm, 40 to 59 mm, ≥ 60 mm. We used competing risks regression to determine differences in the risk of colon cancer-specific mortality between strata after controlling for T stage, tumor grade, age, year of diagnosis, race, and number of dissected lymph nodes.
Median follow-up among censored patients was 12.9 years. We found a significant interaction between lymph node involvement and tumor size (p < 0.05). Among those with node-negative disease, colon cancer-specific mortality increased monotonically with tumor size. In contrast, among those with node-positive disease, patients with the smallest tumors (<5 mm) were at increased risk of 10-year colon cancer-specific mortality compared with those with tumors sized 5 to 19 mm, 20 to 39 mm, 40 to 59 mm, and ≥60 mm (53.3% vs. 30.1%, 37.5%, 39.2%, and 39.7%; adjusted hazard ratios, 1.63-2.24; p < 0.05 in all cases).
The main limitations are the retrospective design and information available in the study database.
In the setting of lymph node involvement, very small tumor size may predict for increased colon cancer-specific mortality compared with larger tumors. Smaller tumors associated with lymph node involvement may represent more aggressive malignancies with a distinct biology that merits further investigation.
传统观点认为,肿瘤体积较大和出现淋巴结转移与结肠癌特异性死亡率增加有关。
我们试图确定,与肿瘤体积较大且出现淋巴结转移的患者相比,肿瘤体积非常小但伴有淋巴结转移的患者的结肠癌特异性死亡风险是否反而会增加。
这是一项使用监测、流行病学和最终结果(SEER)数据库的回顾性队列研究。
采用了18个SEER登记处之一所涵盖的地理区域。
我们确定了1988年至2001年间接受手术治疗的99594例非转移性结肠腺癌患者。
主要预测变量为区域淋巴结转移情况和按最长径计算的原发肿瘤大小,分为以下预先设定的分层:<5mm、5至19mm、20至39mm、40至59mm、≥60mm。在控制T分期、肿瘤分级、年龄、诊断年份、种族和清扫淋巴结数量后,我们使用竞争风险回归来确定各分层之间结肠癌特异性死亡风险的差异。
截尾患者的中位随访时间为12.9年。我们发现淋巴结转移与肿瘤大小之间存在显著交互作用(p<0.05)。在无淋巴结转移的患者中,结肠癌特异性死亡率随肿瘤大小单调增加。相比之下,在有淋巴结转移的患者中,肿瘤体积最小(<5mm)的患者10年结肠癌特异性死亡风险高于肿瘤大小为5至19mm、20至39mm、40至59mm和≥60mm的患者(53.3%对30.1%、37.5%、39.2%和39.7%;校正风险比为1.63 - 2.24;所有情况p<0.05)。
主要局限性在于研究设计为回顾性且研究数据库中的可用信息有限。
在出现淋巴结转移的情况下,与较大肿瘤相比,非常小的肿瘤体积可能预示着结肠癌特异性死亡率增加。伴有淋巴结转移的较小肿瘤可能代表更具侵袭性的恶性肿瘤,其生物学特性独特,值得进一步研究。